The CREDENCE and DAPA-CKD trials have yielded groundbreaking results demonstrating that the new class of antidiabetic agents, known as sodium-glucose co-transporter 2 inhibitors (SGLT2-i), were associated with significantly better kidney endpoints in a DKD population [6, 7]. Here, SLC5A2 is linked to chronic kidney disease.